Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

PBLS

Parabilis Medicines Inc

34.10

Aug 04 • 10:41 AM ET +0.14 (0.40%)

Healthcare Biotechnology USA Mid NASD

Held by: VTI VB VBR VBK ONEQ HLTH TNXT

Scroll to Statements

Index	-
Market Cap	4.03B
Enterprise Value	4.57B
Income	-
Sales	-
Book/sh	-4.83
Cash/sh	2.79
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	Jun 10, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	12.24
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	6.12
Current Ratio	6.12
Debt/Eq	0.22
LT Debt/Eq	0.15
Option/Short	Yes / Yes

EPS (ttm)	-
EPS next Y	-
EPS next Q	-0.17
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	Jun 03
EPS/Sales Surpr.	- -

Insider Own	24.62%
Insider Trans	308.30%
Inst Own	28.39%
Inst Trans	49.37%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	9.42%
SMA50	14.98%
SMA200	14.98%
Trades

Shs Outstand	116.56M
Shs Float	89.06M
Short Float	4.44%
Short Ratio	4.78
Short Interest	3.95M
52W High	34.93 -2.39%
52W Low	24.51 39.11%
Volatility	7.66% 8.50%
ATR (14)	2.52
RSI (14)	60.43
Beta	-
Rel Volume	0.29
Avg Volume	826.81K
Volume	53,925

Perf Week	6.68%
Perf Month	16.76%
Perf Quarter	-
Perf Half Y	-
Perf YTD	2.23%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	41.75
Prev Close	33.96
Price	34.10
Change	0.40%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-06-26	Initiated	Leerink Partners	Outperform	$40
Jul-06-26	Initiated	Guggenheim	Buy	$40
Jul-06-26	Initiated	Evercore ISI	Outperform
Jul-06-26	Initiated	BofA Securities	Buy	$45

Jun-11-26 04:05PM	Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -10.06%
Jun-09-26 08:22PM	Parabilis Medicines Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Fog Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane in 2015 and is headquartered in Cambridge, MA.

Ph.D.Dr. Mathai Mammen M.D.

Executive VPMs. Teresa L. Jurgensen J.D.

Chief Medical OfficerDr. Mohammed Fawzi Benzaghou M.D.

Scientific Co-FounderMr. John McGee Ph.D.

Chief Financial OfficerMr. Thomas Rodolpho Kotarakos

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RA CAPITAL MANAGEMENT, L.P.	Director	Jul 20 '26	Buy	27.28	131,420	3,584,887	26,416,513	Jul 22 04:55 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Jul 21 '26	Buy	29.25	65,923	1,928,032	26,482,436	Jul 22 04:55 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Jul 22 '26	Buy	29.77	47,250	1,406,632	26,529,686	Jul 22 04:55 PM
Levy Guy	10% Owner	Jun 11 '26	Buy	20.00	500,000	10,000,000	1,027,000	Jun 29 10:41 AM
SEBULSKY ALAN	Director	Jun 15 '26	Buy	26.49	9,065	240,135	30,000	Jun 16 06:19 PM
SEBULSKY ALAN	Director	Jun 12 '26	Buy	27.67	8,435	233,393	20,935	Jun 16 06:19 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Jun 11 '26	Buy	20.00	21,188,750	423,775,000	26,285,093	Jun 15 06:57 PM
SEBULSKY ALAN	Director	Jun 11 '26	Buy	20.00	12,500	250,000	12,500	Jun 15 05:27 PM

PBLS

Parabilis Medicines Inc

Upgrade your Finviz experience